The global market for RNAi for Therapeutic was estimated to be worth US$ 176 million in 2023 and is forecast to a readjusted size of US$ 2218 million by 2030 with a CAGR of 43.1% during the forecast period 2024-2030

RNAi for Therapeutic - Market

RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.

Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.

US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.

In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of RNAi for Therapeutic by region & country, by Type, and by Application.

The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.

Market Segmentation

Scope of RNAi for Therapeutic - Market Report

Report Metric	Details
Report Name	RNAi for Therapeutic - Market
Forecasted market size in 2030	US$ 2218 million
CAGR	43.1%
Forecasted years	2024 - 2030
Segment by Type:	siRNA miRNA shRNA
Segment by Application	Cancer Cardiovascular HBV Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Silence Therapeutics, Benitec Biopharma, miRagen Therapeutics, Sylentis, Gradalis, Sirnaomics, Silenseed
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of RNAi for Therapeutic manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of RNAi for Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of RNAi for Therapeutic in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the RNAi for Therapeutic - Market size in 2030?

Ans: The RNAi for Therapeutic - Market size in 2030 will be US$ 2218 million.

What is the market share of major companies in RNAi for Therapeutic - Market?

Ans: Global top five manufacturers hold a share over 85%.

What is the RNAi for Therapeutic - Market share by type?

Ans: In terms of product, siRNA is the largest segment, with a share over 55%.

Who are the main players in the RNAi for Therapeutic - Market report?

Ans: The main players in the RNAi for Therapeutic - Market are Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Silence Therapeutics, Benitec Biopharma, miRagen Therapeutics, Sylentis, Gradalis, Sirnaomics, Silenseed

What are the Application segmentation covered in the RNAi for Therapeutic - Market report?

Ans: The Applications covered in the RNAi for Therapeutic - Market report are Cancer, Cardiovascular, HBV, Others

What are the Type segmentation covered in the RNAi for Therapeutic - Market report?

Ans: The Types covered in the RNAi for Therapeutic - Market report are siRNA, miRNA, shRNA

1 Market Overview

1.1 RNAi for Therapeutic Product Introduction

1.2 Global RNAi for Therapeutic Market Size Forecast

1.3 RNAi for Therapeutic Market Trends & Drivers

1.3.1 RNAi for Therapeutic Industry Trends

1.3.2 RNAi for Therapeutic Market Drivers & Opportunity

1.3.3 RNAi for Therapeutic Market Challenges

1.3.4 RNAi for Therapeutic Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global RNAi for Therapeutic Players Revenue Ranking (2023)

2.2 Global RNAi for Therapeutic Revenue by Company (2019-2024)

2.3 Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters

2.4 Key Companies RNAi for Therapeutic Product Offered

2.5 Key Companies Time to Begin Mass Production of RNAi for Therapeutic

2.6 RNAi for Therapeutic Market Competitive Analysis

2.6.1 RNAi for Therapeutic Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by RNAi for Therapeutic Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 siRNA

3.1.2 miRNA

3.1.3 shRNA

3.2 Global RNAi for Therapeutic Sales Value by Type

3.2.1 Global RNAi for Therapeutic Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global RNAi for Therapeutic Sales Value, by Type (2019-2030)

3.2.3 Global RNAi for Therapeutic Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Cancer

4.1.2 Cardiovascular

4.1.3 HBV

4.1.4 Others

4.2 Global RNAi for Therapeutic Sales Value by Application

4.2.1 Global RNAi for Therapeutic Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global RNAi for Therapeutic Sales Value, by Application (2019-2030)

4.2.3 Global RNAi for Therapeutic Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global RNAi for Therapeutic Sales Value by Region

5.1.1 Global RNAi for Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global RNAi for Therapeutic Sales Value by Region (2019-2024)

5.1.3 Global RNAi for Therapeutic Sales Value by Region (2025-2030)

5.1.4 Global RNAi for Therapeutic Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America RNAi for Therapeutic Sales Value, 2019-2030

5.2.2 North America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe RNAi for Therapeutic Sales Value, 2019-2030

5.3.2 Europe RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific RNAi for Therapeutic Sales Value, 2019-2030

5.4.2 Asia Pacific RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America RNAi for Therapeutic Sales Value, 2019-2030

5.5.2 South America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa RNAi for Therapeutic Sales Value, 2019-2030

5.6.2 Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions RNAi for Therapeutic Sales Value

6.3 United States

6.3.1 United States RNAi for Therapeutic Sales Value, 2019-2030

6.3.2 United States RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

6.3.3 United States RNAi for Therapeutic Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe RNAi for Therapeutic Sales Value, 2019-2030

6.4.2 Europe RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe RNAi for Therapeutic Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China RNAi for Therapeutic Sales Value, 2019-2030

6.5.2 China RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

6.5.3 China RNAi for Therapeutic Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan RNAi for Therapeutic Sales Value, 2019-2030

6.6.2 Japan RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan RNAi for Therapeutic Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea RNAi for Therapeutic Sales Value, 2019-2030

6.7.2 South Korea RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea RNAi for Therapeutic Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia RNAi for Therapeutic Sales Value, 2019-2030

6.8.2 Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia RNAi for Therapeutic Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India RNAi for Therapeutic Sales Value, 2019-2030

6.9.2 India RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

6.9.3 India RNAi for Therapeutic Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Alnylam Pharmaceuticals

7.1.1 Alnylam Pharmaceuticals Profile

7.1.2 Alnylam Pharmaceuticals Main Business

7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

7.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.1.5 Alnylam Pharmaceuticals Recent Developments

7.2 Arbutus Biopharma (Tekmira)

7.2.1 Arbutus Biopharma (Tekmira) Profile

7.2.2 Arbutus Biopharma (Tekmira) Main Business

7.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products, Services and Solutions

7.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.2.5 Arbutus Biopharma (Tekmira) Recent Developments

7.3 Arrowhead

7.3.1 Arrowhead Profile

7.3.2 Arrowhead Main Business

7.3.3 Arrowhead RNAi for Therapeutic Products, Services and Solutions

7.3.4 Arrowhead RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.3.5 Dicerna Pharmaceuticals Recent Developments

7.4 Dicerna Pharmaceuticals

7.4.1 Dicerna Pharmaceuticals Profile

7.4.2 Dicerna Pharmaceuticals Main Business

7.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

7.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.4.5 Dicerna Pharmaceuticals Recent Developments

7.5 Mirna Therapeutics

7.5.1 Mirna Therapeutics Profile

7.5.2 Mirna Therapeutics Main Business

7.5.3 Mirna Therapeutics RNAi for Therapeutic Products, Services and Solutions

7.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.5.5 Mirna Therapeutics Recent Developments

7.6 Quark Pharmaceuticals

7.6.1 Quark Pharmaceuticals Profile

7.6.2 Quark Pharmaceuticals Main Business

7.6.3 Quark Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

7.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.6.5 Quark Pharmaceuticals Recent Developments

7.7 RXi Pharmaceuticals

7.7.1 RXi Pharmaceuticals Profile

7.7.2 RXi Pharmaceuticals Main Business

7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

7.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.7.5 RXi Pharmaceuticals Recent Developments

7.8 Silence Therapeutics

7.8.1 Silence Therapeutics Profile

7.8.2 Silence Therapeutics Main Business

7.8.3 Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions

7.8.4 Silence Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.8.5 Silence Therapeutics Recent Developments

7.9 Benitec Biopharma

7.9.1 Benitec Biopharma Profile

7.9.2 Benitec Biopharma Main Business

7.9.3 Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions

7.9.4 Benitec Biopharma RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.9.5 Benitec Biopharma Recent Developments

7.10 miRagen Therapeutics

7.10.1 miRagen Therapeutics Profile

7.10.2 miRagen Therapeutics Main Business

7.10.3 miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions

7.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.10.5 miRagen Therapeutics Recent Developments

7.11 Sylentis

7.11.1 Sylentis Profile

7.11.2 Sylentis Main Business

7.11.3 Sylentis RNAi for Therapeutic Products, Services and Solutions

7.11.4 Sylentis RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.11.5 Sylentis Recent Developments

7.12 Gradalis

7.12.1 Gradalis Profile

7.12.2 Gradalis Main Business

7.12.3 Gradalis RNAi for Therapeutic Products, Services and Solutions

7.12.4 Gradalis RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.12.5 Gradalis Recent Developments

7.13 Sirnaomics

7.13.1 Sirnaomics Profile

7.13.2 Sirnaomics Main Business

7.13.3 Sirnaomics RNAi for Therapeutic Products, Services and Solutions

7.13.4 Sirnaomics RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.13.5 Sirnaomics Recent Developments

7.14 Silenseed

7.14.1 Silenseed Profile

7.14.2 Silenseed Main Business

7.14.3 Silenseed RNAi for Therapeutic Products, Services and Solutions

7.14.4 Silenseed RNAi for Therapeutic Revenue (US$ Million) & (2019-2024)

7.14.5 Silenseed Recent Developments

8 Industry Chain Analysis

8.1 RNAi for Therapeutic Industrial Chain

8.2 RNAi for Therapeutic Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 RNAi for Therapeutic Sales Model

8.5.2 Sales Channel

8.5.3 RNAi for Therapeutic Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

List of Tables

Table 1. RNAi for Therapeutic Market Trends

Table 2. RNAi for Therapeutic Market Drivers & Opportunity

Table 3. RNAi for Therapeutic Market Challenges

Table 4. RNAi for Therapeutic Market Restraints

Table 5. Global RNAi for Therapeutic Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global RNAi for Therapeutic Revenue Market Share by Company (2019-2024)

Table 7. Key Companies RNAi for Therapeutic Manufacturing Base Distribution and Headquarters

Table 8. Key Companies RNAi for Therapeutic Product Type

Table 9. Key Companies Time to Begin Mass Production of RNAi for Therapeutic

Table 10. Global RNAi for Therapeutic Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global RNAi for Therapeutic Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global RNAi for Therapeutic Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global RNAi for Therapeutic Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global RNAi for Therapeutic Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global RNAi for Therapeutic Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global RNAi for Therapeutic Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global RNAi for Therapeutic Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global RNAi for Therapeutic Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global RNAi for Therapeutic Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global RNAi for Therapeutic Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global RNAi for Therapeutic Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global RNAi for Therapeutic Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global RNAi for Therapeutic Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global RNAi for Therapeutic Sales Value by Region (2019-2024) & (%)

Table 27. Global RNAi for Therapeutic Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions RNAi for Therapeutic Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions RNAi for Therapeutic Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions RNAi for Therapeutic Sales Value, (2025-2030) & (US$ Million)

Table 31. Alnylam Pharmaceuticals Basic Information List

Table 32. Alnylam Pharmaceuticals Description and Business Overview

Table 33. Alnylam Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

Table 34. Revenue (US$ Million) in RNAi for Therapeutic Business of Alnylam Pharmaceuticals (2019-2024)

Table 35. Alnylam Pharmaceuticals Recent Developments

Table 36. Arbutus Biopharma (Tekmira) Basic Information List

Table 37. Arbutus Biopharma (Tekmira) Description and Business Overview

Table 38. Arbutus Biopharma (Tekmira) RNAi for Therapeutic Products, Services and Solutions

Table 39. Revenue (US$ Million) in RNAi for Therapeutic Business of Arbutus Biopharma (Tekmira) (2019-2024)

Table 40. Arbutus Biopharma (Tekmira) Recent Developments

Table 41. Arrowhead Basic Information List

Table 42. Arrowhead Description and Business Overview

Table 43. Arrowhead RNAi for Therapeutic Products, Services and Solutions

Table 44. Revenue (US$ Million) in RNAi for Therapeutic Business of Arrowhead (2019-2024)

Table 45. Arrowhead Recent Developments

Table 46. Dicerna Pharmaceuticals Basic Information List

Table 47. Dicerna Pharmaceuticals Description and Business Overview

Table 48. Dicerna Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

Table 49. Revenue (US$ Million) in RNAi for Therapeutic Business of Dicerna Pharmaceuticals (2019-2024)

Table 50. Dicerna Pharmaceuticals Recent Developments

Table 51. Mirna Therapeutics Basic Information List

Table 52. Mirna Therapeutics Description and Business Overview

Table 53. Mirna Therapeutics RNAi for Therapeutic Products, Services and Solutions

Table 54. Revenue (US$ Million) in RNAi for Therapeutic Business of Mirna Therapeutics (2019-2024)

Table 55. Mirna Therapeutics Recent Developments

Table 56. Quark Pharmaceuticals Basic Information List

Table 57. Quark Pharmaceuticals Description and Business Overview

Table 58. Quark Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

Table 59. Revenue (US$ Million) in RNAi for Therapeutic Business of Quark Pharmaceuticals (2019-2024)

Table 60. Quark Pharmaceuticals Recent Developments

Table 61. RXi Pharmaceuticals Basic Information List

Table 62. RXi Pharmaceuticals Description and Business Overview

Table 63. RXi Pharmaceuticals RNAi for Therapeutic Products, Services and Solutions

Table 64. Revenue (US$ Million) in RNAi for Therapeutic Business of RXi Pharmaceuticals (2019-2024)

Table 65. RXi Pharmaceuticals Recent Developments

Table 66. Silence Therapeutics Basic Information List

Table 67. Silence Therapeutics Description and Business Overview

Table 68. Silence Therapeutics RNAi for Therapeutic Products, Services and Solutions

Table 69. Revenue (US$ Million) in RNAi for Therapeutic Business of Silence Therapeutics (2019-2024)

Table 70. Silence Therapeutics Recent Developments

Table 71. Benitec Biopharma Basic Information List

Table 72. Benitec Biopharma Description and Business Overview

Table 73. Benitec Biopharma RNAi for Therapeutic Products, Services and Solutions

Table 74. Revenue (US$ Million) in RNAi for Therapeutic Business of Benitec Biopharma (2019-2024)

Table 75. Benitec Biopharma Recent Developments

Table 76. miRagen Therapeutics Basic Information List

Table 77. miRagen Therapeutics Description and Business Overview

Table 78. miRagen Therapeutics RNAi for Therapeutic Products, Services and Solutions

Table 79. Revenue (US$ Million) in RNAi for Therapeutic Business of miRagen Therapeutics (2019-2024)

Table 80. miRagen Therapeutics Recent Developments

Table 81. Sylentis Basic Information List

Table 82. Sylentis Description and Business Overview

Table 83. Sylentis RNAi for Therapeutic Products, Services and Solutions

Table 84. Revenue (US$ Million) in RNAi for Therapeutic Business of Sylentis (2019-2024)

Table 85. Sylentis Recent Developments

Table 86. Gradalis Basic Information List

Table 87. Gradalis Description and Business Overview

Table 88. Gradalis RNAi for Therapeutic Products, Services and Solutions

Table 89. Revenue (US$ Million) in RNAi for Therapeutic Business of Gradalis (2019-2024)

Table 90. Gradalis Recent Developments

Table 91. Sirnaomics Basic Information List

Table 92. Sirnaomics Description and Business Overview

Table 93. Sirnaomics RNAi for Therapeutic Products, Services and Solutions

Table 94. Revenue (US$ Million) in RNAi for Therapeutic Business of Sirnaomics (2019-2024)

Table 95. Sirnaomics Recent Developments

Table 96. Silenseed Basic Information List

Table 97. Silenseed Description and Business Overview

Table 98. Silenseed RNAi for Therapeutic Products, Services and Solutions

Table 99. Revenue (US$ Million) in RNAi for Therapeutic Business of Silenseed (2019-2024)

Table 100. Silenseed Recent Developments

Table 101. Key Raw Materials Lists

Table 102. Raw Materials Key Suppliers Lists

Table 103. RNAi for Therapeutic Downstream Customers

Table 104. RNAi for Therapeutic Distributors List

Table 105. Research Programs/Design for This Report

Table 106. Key Data Information from Secondary Sources

Table 107. Key Data Information from Primary Sources

Table 108. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. RNAi for Therapeutic Product Picture

Figure 2. Global RNAi for Therapeutic Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)

Figure 4. RNAi for Therapeutic Report Years Considered

Figure 5. Global RNAi for Therapeutic Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by RNAi for Therapeutic Revenue in 2023

Figure 7. RNAi for Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. siRNA Picture

Figure 9. miRNA Picture

Figure 10. shRNA Picture

Figure 11. Global RNAi for Therapeutic Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global RNAi for Therapeutic Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Cancer

Figure 14. Product Picture of Cardiovascular

Figure 15. Product Picture of HBV

Figure 16. Product Picture of Others

Figure 17. Global RNAi for Therapeutic Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global RNAi for Therapeutic Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)

Figure 20. North America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

Figure 25. South America RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)

Figure 26. South America RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa RNAi for Therapeutic Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa RNAi for Therapeutic Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions RNAi for Therapeutic Sales Value (%), (2019-2030)

Figure 30. United States RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

Figure 32. United States RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030

Figure 36. China RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)

Figure 37. China RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

Figure 38. China RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030

Figure 48. India RNAi for Therapeutic Sales Value, (2019-2030) & (US$ Million)

Figure 49. India RNAi for Therapeutic Sales Value by Type (%), 2023 VS 2030

Figure 50. India RNAi for Therapeutic Sales Value by Application (%), 2023 VS 2030

Figure 51. RNAi for Therapeutic Industrial Chain

Figure 52. RNAi for Therapeutic Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions